Home › Drugs A to Z › A › Ar › Aripiprazole Pregnancy Warnings
Print Save or Share

Aripiprazole Pregnancy and Breastfeeding Warnings

Aripiprazole is also known as: Abilify, Abilify Discmelt

Overview

It is not known if Aripiprazole Orally Disintegrating Tablets can cause harm to the fetus. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Aripiprazole Orally Disintegrating Tablets while you are pregnant. Using Aripiprazole Orally Disintegrating Tablets during the third trimester may result in uncontrolled muscle movements or withdrawal symptoms in the newborn. Discuss any questions or concerns with your doctor. It is not known if Aripiprazole Orally Disintegrating Tablets are found in breast milk. Do not breast-feed while taking Aripiprazole Orally Disintegrating Tablets.

Aripiprazole Pregnancy Warnings

According to 1 case report, exposure to aripiprazole (10 mg/day initially then increased to 15 mg/day over 2 weeks) at week 29 of gestation until 6 days prior to delivery did not result in adverse peri- or post- natal effects.

Aripiprazole has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of developmental toxicity, including possible teratogenic effects. There are no controlled data in human pregnancy. Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization. Aripiprazole should only be given during pregnancy if the potential benefits outweigh the potential risks.

Aripiprazole Breastfeeding Warnings

There are no data on the excretion of aripiprazole into human milk. The manufacturer recommends that women receiving aripiprazole should not breast-feed.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

(web2)